acoramidis 356 MG Oral Tablet
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
acoramidis 356 MG Oral Tablet
356 MG · Oral Tablet · oral
A form of acoramidis →
acoramidis 356 MG Oral Tablet — Other cardiac preparations. INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM
Active ingredient
Classification
Other cardiac preparations
Drug interactions
Acoramidis has several drug interactions that may affect its metabolism and the metabolism of other drugs.
- majorUGT inducers — decreased acoramidis exposure
- majorstrong CYP3A inducers — decreased acoramidis exposure
- moderatesensitive CYP2C9 substrates — increased CYP2C9 substrate concentrations
Real-world adverse events (FAERS)
Diarrhoea45Fatigue16Dizziness15Abdominal Discomfort14Blood Creatinine Increased12Nausea11Asthenia10Dyspnoea10
Indications
INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )
Dosage
DOSAGE AND ADMINISTRATION The recommended dosage of ATTRUBY is 712 mg orally twice daily. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of ATTRUBY is 712 mg orally twice daily (with or without food). Swallow tablets whole; do not cut, crush, or chew.
Contraindications
CONTRAINDICATIONS None. None. ( 4 ) To report SUSPECTED ADVERSE REACTIONS, contact BridgeBio Pharma Inc. at 1-844-550-2246 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Mechanism of action
Mechanism of Action Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.
Indicated ICD-10 codes
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication